Abeona Therapeutics Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Abeona Therapeutics Inc.Headquarters: New York, 
                        NY, United States
                    
Employees: 76
CEO: Dr. Vishwas  Seshadri M.B.A., Ph.D.

                                    NASDAQ: ABEO
                                
                                            +4.09%
                                            
Market Cap$140.2 Million

                        USD as of Jan. 1, 2024
                    
                            Market Cap History

Abeona Therapeutics Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Abeona Therapeutics Inc. market capitalization over time

Evolution of Abeona Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Abeona Therapeutics Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$461.52 B
Vertex Pharmaceuticals Incorporated	$107.23 B
Regeneron Pharmaceuticals, Inc.	$100.01 B
CSL Limited	$94.74 B
Marinomed Biotech AG	$73.23 B

Sector:

Company	Market Cap (USD)
Lilly	$586.39 B
UnitedHealth Group	$504.47 B
Novo Nordisk	$461.52 B
Johnson & Johnson	$387.50 B
Merck	$296.51 B

Detailed Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

Tweets by Abeona Therapeutics Inc.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE